Are you need IT Support Engineer? Free Consultant
Report ID: HC0045
Pages: 174
Base Year: 2023
Format: PDF
Historical Date: 2019-2022
MARKET SCOPE:
The global Targeted DNA Sequencing market is projected to grow significantly, registering a CAGR of 12.1% during the forecast period (2024 – 2032).
Targeted DNA sequencing is an approach to high-throughput sequencing that selectively captures and sequences specific segments of the genome rather than the entire genomic content. This methodology enables researchers to concentrate on particular genomic regions of interest, providing a cost-effective and efficient means to analyze targeted genes or specific genomic areas. Researchers have the flexibility to choose particular genomic regions, such as coding sequences, exons, or regions linked to specific diseases, for targeted sequencing, resulting in a more focused analysis compared to whole-genome sequencing. The process of targeted DNA sequencing involves the creation of a sequencing library designed to selectively capture the identified genomic regions. This is commonly achieved through the utilization of DNA probes or baits that selectively bind to the specified regions of interest. Subsequently, the prepared library undergoes a capture or enrichment step, isolating the targeted genomic regions. This critical step ensures that the sequenced data predominantly originates from the selected regions, enhancing the precision and relevance of the analysis.
MARKET OVERVIEW:
Driver: Technological advancements in DNA sequencing, increasing application in clinical diagnosis and drug discovery is driving the market growth.
The progress in DNA sequencing technologies has significantly propelled market growth. According to the NHGRI, advancements and enhancements in technology have rapidly evolved and reduced costs since the completion of the Human Genome Project. As a result, some laboratories are now capable of sequencing over 100 trillion bases annually. Notable DNA sequencing equipment such as Biomek 4000, Hudson Robotics SOLO, Formulatrix Mantis, Hamilton Microlab NIMBUS, Hamilton Genomic STARlet, Eppendorf epMotion 5075t, Beckman Coulter Biomek i5, Tecan NGS, PerkinElmer Sciclone G3 NGS and NGSx Workstation, Hamilton NGS STAR, Beckman Coulter Biomek i7, and Agilent Bravo NGS have played a crucial role in refining the DNA sequencing process.
Opportunities: Continued research and development activities as well as growing usage of novel procedures are expected to pave the way for market growth in the upcoming years.
The market growth is anticipated to receive a significant boost due to the increasing adoption of advanced DNA sequencing techniques. Emerging procedures such as high-throughput sequencing, ion-torrent sequencing, pyrosequencing, single-molecule real-time sequencing, sequencing by synthesis, sequencing by ligation, combinatorial probe anchor synthesis, GenapSys sequencing, Sanger sequencing, and Nanopore sequencing leverage various technologies including electrical tunnelling, hybridization, mass spectrometry, in vitro virus mRNA display, microscopy, and microfluidics. These methods find applications in DNA sequencing, DNA synthesis, RNA sequencing, gene sequencing, as well as sample preparation for DNA and RNA polymerase. The incorporation of these diverse and innovative techniques is expected to create ample growth opportunities for the market in the future.
COVID IMPACT:
The global market for targeted DNA sequencing, akin to various industries, has felt the repercussions of the COVID-19 pandemic. The outbreak resulted in disruptions within supply chains, obstacles in research and development initiatives, and a realignment of healthcare priorities. As the healthcare sector confronted the overwhelming demands of addressing the pandemic, resources were redirected from routine diagnostics and research pursuits, impacting the progression of targeted DNA sequencing projects. Furthermore, lockdowns, travel restrictions, and adherence to social distancing measures disrupted the regular operations of laboratories and research facilities, causing delays in sample processing and data generation. Despite these challenges, the pandemic highlighted the significance of genomics in comprehending infectious diseases, reigniting interest in targeted DNA sequencing for scrutinizing the genetic aspects of the virus and its effects on host populations. Anticipated recovery is on the horizon as research activities resume, and the emphasis on personalized medicine and genomic research gains momentum in the post-pandemic landscape. The ongoing advancements in the targeted DNA sequencing market continue to shape the industry’s strategies in response to the evolving challenges posed by the global health crisis.
SEGMENTATION ANALYSIS:
The sequencing segment is anticipated to grow significantly during the forecast period.
As sequencing costs decrease and throughput capability improves, sequencing is gaining momentum across various applications, with an increasing number of companies integrating Next-Generation Sequencing (NGS) into clinical practices. This trend is anticipated to persist in the clinical setting in the coming years, propelled by market opportunities in areas such as liquid biopsy and average-risk Non-Invasive Prenatal Testing (NIPT). In January 2021, Illumina announced several oncology partnerships with Merck, Myriad Genetics, Kura Oncology, and Bristol Myers Squibb, aiming to expand the utilization and reach of its TruSight Oncology pan-cancer assay.
The hospital segment is anticipated to grow significantly during the forecast period.
The segment encompassing hospitals and clinics is expected to experience substantial growth, driven by a growing number of patients seeking personalized care. The increased adoption of Next-Generation Sequencing (NGS) services in hospitals and clinics, aimed at assessing disease progression rates and optimizing tailored treatment plans for chronic conditions, has been a key contributor to the segment’s expansion. Leading market players like Illumina, offering clinical services such as CLIA-certified tests for predisposition screening, molecular diagnostic tests for cystic fibrosis, and postnatal cytogenetics, are poised to contribute significantly to revenue growth in the foreseeable future.
REGIONAL ANALYSIS:
The Asia Pacific region is set to witness significant growth during the forecast period.
The Asia Pacific market is expected to experience accelerated growth in the foreseeable future, attributed to the rising expenditure on research and development, coupled with the availability of advanced technology for drug discovery and development. Notably, Japan and China have witnessed noteworthy advancements in integrating Next-Generation Sequencing (NGS) technologies, aligning with the clinical development frameworks of emerging economies like Australia and India, thereby presenting substantial growth prospects. In August 2022, Illumina unveiled plans to expand its regional presence by establishing a new manufacturing unit in China, aimed at supplying gene sequencing products. This strategic move reflects the company’s commitment to tapping into the growing opportunities within the dynamic Asia Pacific market.
COMPETITIVE ANALYSIS
The global Targeted DNA Sequencing market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.
Scope of the Report
** In – depth qualitative analysis will be provided in the final report subject to market
Primary and Secondary Research
In order to understand the market in detail we conduct primary and secondary research. We collect as much information as we can from the market experts through primary research. We contact the experts from both demand and supply side and conduct interviews to understand the actual market scenario. In secondary research, we study and gather the data from various secondary sources such as company annual reports, press releases, whitepapers, paid databases, journals, and many other online sources. With the help of the primary interviews, we validate the data collected from secondary sources and get a deep understanding on the subject matter. Post this our team uses statistical tools to analyses the data to arrive at a conclusion and draft it in presentable manner.
Market Size Estimations
Understanding and presenting the data collected is a crucial task. Market sizing is a critical part of the data analysis and this task is performed by using Top-down and bottom-up approaches. In this process, we place different data points, market information and industry trends at a suitable space. This placement helps us presume the estimated & forecast values for coming few years. We use several mathematical and statistical models to estimate the market sizes of different countries and segments. Each of this is further added up to outline the total market. These approaches are individually done on regional/country and segment level.
Data Triangulation
As we arrive at the total market sizes, the market is again broken down into segments and subsegments. This process is called as data triangulation and is implementable wherever applicable. This step not only helps us conclude the overall market engineering process, but also gives an assurance on accuracy of the data generated. The data is triangulated based on studying the market trends, various growth factors, and aspects of both demand and supply side.